Skip to main content
. 2021 Jan 22;11:2097. doi: 10.1038/s41598-021-81639-0

Figure 1.

Figure 1

LRRK2-low lung adenocarcinoma is associated with poor patient survival, non-TRU expression-based molecular subtypes and worse predicted tumor differentiation. (A) Plot of LRRK2 mRNA levels in LUAD tumors (dichotomized into LRRK2-low and -high expression groups) and adjacent normal lung tissue (RSEM values), from TCGA LUAD patients. (B) Kaplan–Meier plot of LUAD patient OS or DSS stratified by LRRK2 expression status. (C) Pairwise Fisher’s exact test for enrichment of expression subtype frequency within LRRK2 expression groups: TRU-like versus non-TRU type LUAD. (D) (Left) Standardized LRRK2 tumoral expression per sample (RSEM values), annotated for lower risk TRU-like or higher risk non-TRU type tumors or (Right) grouped by the combined status for LRRK2 expression and expression subtype (median centred boxplot of RSEM values). (E) Pairwise Fisher’s exact test for enrichment of smoking history within LRRK2 expression groups: TRU-like versus non-TRU type LUAD. (F) Correlation of LRRK2 expression with a previously published gene expression-based score representing LUAD tumor differentiation status (Spearman’s correlation coefficient − 0.59 with Holm’s adjP < 0.0001; positive scores represent increasingly poor differentiation). (G) Stratification of the tumoral gene expression of established markers for alveolar and bronchiolar epithelial cell types, by the combined LRRK2 and expression subtype status of LUAD tumors (median-centred boxplot of standardized RSEM values; Dunn’s test BH adjP < 0.05).